Novogen Limited (NASDAQ:KZIA) Short Interest Update

Novogen Limited (NASDAQ:KZIA) saw a large drop in short interest in January. As of January 15th, there was short interest totaling 86,745 shares, a drop of 44.2% from the December 31st total of 155,365 shares. Based on an average daily volume of 292,964 shares, the short-interest ratio is currently 0.3 days. Currently, 5.3% of the shares of the stock are sold short. Currently, 5.3% of the shares of the stock are sold short. Based on an average daily volume of 292,964 shares, the short-interest ratio is currently 0.3 days.

Novogen Stock Performance

Shares of KZIA traded down $0.24 during mid-day trading on Friday, hitting $5.86. 293,974 shares of the company’s stock were exchanged, compared to its average volume of 275,475. The firm has a fifty day moving average of $8.78 and a two-hundred day moving average of $8.14. Novogen has a twelve month low of $2.86 and a twelve month high of $17.40.

Novogen (NASDAQ:KZIA) last posted its earnings results on Friday, November 7th. The company reported ($6.14) EPS for the quarter. The business had revenue of $0.59 million for the quarter.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KZIA. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Novogen in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Novogen in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Novogen to a “hold” rating in a report on Saturday, November 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Novogen currently has a consensus rating of “Hold” and an average target price of $19.00.

About Novogen

Novogen (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide.